The vast majority of providers accept pharmacist-initiated recommendations to screen for hepatitis B virus (HBV) in patients started on oral oncolytics, according to a new study presented at NASP 2024, in Nashville, Tenn.
These interventions led to a significant increase in the percentage of patients screened, which optimized patient safety before initiating treatment, reported Anthony Angyal, PharmD, a clinical oncology pharmacist for Cleveland Clinic Specialty Pharmacy (CCSP).
Ensuring optimal